Valeant begins look like normal drug pany with much debt

VRX Stock Price - Valeant Pharmaceuticals International Inc. Stock ... » Valeant Pharmaceuticals International Inc. stock price, stock quotes and financial overviews from MarketWatch. Marketwatch.com

A Valeant Update: Damaged Goods Or Deeply Discounted Drug ... » Mar 24, 2017 ...That idiom, unfortunately, is what came to mind as I took another look at Valeant ( NYSE:VRX), the vessel in my investment portfolio that most closely ...My belief then was that the company's business model, built on acquisitions, debt and drug repricing, was broken and that the company, if it became a more... Seekingalpha.com

Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Back From the Abyss » Jul 21, 2017 ...Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is back from the dead. The company that crashed and nearly burned up on a strategy of debt-based acquisitions and dicey sales strategies has been making a quiet comeback in 2017, this time in the garb of a chastened, almost-normal drug company. Investorplace.com

How Much Is Valeant Pharmaceuticals Really Worth? -- The Motley ... » Jun 17, 2016 ...With Valeant's pricing practices being monitored like a hawk, it could wind up losing the most valuable asset of a drug developer: pricing power. ....However, Valeant's debt situation is becoming more dire with each passing day, and I believe that will begin weighing on Valeant's valuation as the asset sales... Fool.com

Valeant: A timeline of the big Pharma scandal | Fortune » Oct 31, 2015 ...October 6: Hedge fund Bill Ackman, and one of the Valeant's largest shareholders, defends the drug company's strategy saying it does a lot more to spur research and ...But Hempton's cryptic post, written like a scene out of The Graduate, offers no clues as what Philidor is, or that it is connected to Valeant. Fortune.com

Funds Face Off on Valeant | SumZero » Mar 1, 2016 ...However, Valeant's return on invested capital (ROIC), which provides a true measure of if/how much value the company creates, had fallen from 15% in 2009 to 4% in 2013. The prior acquisitions ....The debate is what earnings look like 5 years from now (when Xifaxan and Jublia patents begin to roll off). Sumzero.com

Valeant Pharmaceuticals Intl Inc (VRX) Stock Is a Great Speculative ... » Jun 15, 2017 ...Then look no further than Valeant Pharmaceuticals Intl Inc (NYSE:VRX). VRX stock has been on the rebound since I last wrote about the much-maligned — and rightfully so — drug company in late March. Given the ...Are you a contrarian , but also like the company of a storied value investor on your side? Finance.yahoo.com

Valeant Begins To Look Like A Normal Drug Company, But With ... » Aug 9, 2016 ...The "new" Valeant Pharmaceuticals - a kinder and gentler rendition of the most hated company in the pharma industry - surprised Wall Street on Tuesday morning by reaffirming its 2016 financial guidance and capably ...Valeant Begins To Look Like A Normal Drug Company, But With Way Too Much Debt. Forbes.com

Valeant not profitable as normal drug co - Business Insider » Mar 22, 2016 ...Valeant, working as a normal drug company that spends money on research and development and does not price gouge or use debt-filled takeovers to grow, ... analysts wondered how much product Valeant was going to give away for free, and, unlike with Philidor, the drugs are being sold on consignment. Businessinsider.com

Hedge Fund Titan's Surefire Bet Turns Into a $4 Billion Loss - The ... » Mar 19, 2017 ...As much as Mr. Ackman and investors in his $11 billion firm would like to close the book on Valeant, they cannot do so quite yet. ....congressional hearings about escalating drug prices in April, Mr. Ackman apologized for Valeant's mistakes, vowing to use his position on the board to change the company. Nytimes.com